Aragon Pharmaceuticals, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Registration Number
- NCT03523338
- Locations
- π§π·
Ynova Pesquisa Clinica, Florianopolis, Brazil
π§π·Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil
π§π·Fundacao Antonio Prudente - A.C. Camargo Cancer Center, Sao Paulo, Brazil
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Phase 1
Recruiting
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02592317
- Locations
- π²π©
Arensia Exploratory Medicine, Chisinau, Moldova, Republic of
πͺπΈHosp Univ Vall D Hebron, Barcelona, Spain
πͺπΈHosp. Virgen Del Rocio, Sevilla, Spain
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02578797
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Phase 3
Active, not recruiting
- Conditions
- Prostatic Neoplasms
- Interventions
- Radiation: 74-80 Grays (units of radiation)
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 1503
- Registration Number
- NCT02531516
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02524717
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Phase 3
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 1052
- Registration Number
- NCT02489318
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 3
Active, not recruiting
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 982
- Registration Number
- NCT02257736
Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02230033
Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ-56021927 Tablet Formulation 3Drug: JNJ-56021927 Softgel CapsuleDrug: JNJ-56021927 Tablet Formulation 2Drug: JNJ-56021927 Tablet Formulation 1
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT02160756
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 1
Active, not recruiting
- Conditions
- Prostatic NeoplasmsMetastatic Castration-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT02123758
Β© Copyright 2025. All Rights Reserved by MedPath